LUXIQ Drug Patent Profile
✉ Email this page to a colleague
When do Luxiq patents expire, and when can generic versions of Luxiq launch?
Luxiq is a drug marketed by Quagen and is included in one NDA.
The generic ingredient in LUXIQ is betamethasone valerate. Twelve suppliers are listed for this compound. Additional details are available on the betamethasone valerate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Luxiq
A generic version of LUXIQ was approved as betamethasone valerate by FOUGERA on August 31st, 1983.
Paragraph IV (Patent) Challenges for LUXIQ
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| LUXIQ | Foam | betamethasone valerate | 0.12% | 020934 | 1 | 2007-08-10 |
US Patents and Regulatory Information for LUXIQ
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Quagen | LUXIQ | betamethasone valerate | AEROSOL, FOAM;TOPICAL | 020934-001 | Feb 28, 1999 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for LUXIQ
See the table below for patents covering LUXIQ around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 253367 | ⤷ Start Trial | |
| Australia | 4885196 | ⤷ Start Trial | |
| Australia | 709320 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
